Alphatec Sees Unusually Large Options Volume (NASDAQ:ATEC)

Alphatec Holdings, Inc. (NASDAQ:ATEC) was the recipient of some unusual options trading activity on Tuesday. Stock traders acquired 4,816 put options on the stock. This is an increase of 246% compared to the average volume of 1,392 put options.

Insider Buying and Selling at Alphatec

In related news, CEO Patrick Miles sold 12,691 shares of Alphatec stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the sale, the chief executive officer now directly owns 5,857,603 shares of the company’s stock, valued at approximately $62,324,895.92. This trade represents a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Scott Lish sold 27,453 shares of Alphatec stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total value of $315,434.97. Following the sale, the chief operating officer now directly owns 867,677 shares of the company’s stock, valued at $9,969,608.73. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 278,800 shares of company stock valued at $3,201,469 in the last three months. 22.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alphatec

Institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Alphatec by 38,433.3% in the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company’s stock worth $228,000 after acquiring an additional 2,306 shares during the period. Comerica Bank lifted its position in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 1,248 shares during the period. R Squared Ltd bought a new stake in shares of Alphatec in the 4th quarter valued at $29,000. Nisa Investment Advisors LLC increased its position in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after buying an additional 4,234 shares during the period. Finally, Quarry LP raised its stake in Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after buying an additional 2,375 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Trading Down 2.8 %

Shares of NASDAQ:ATEC traded down $0.29 during midday trading on Tuesday, hitting $9.89. 817,235 shares of the stock were exchanged, compared to its average volume of 2,026,123. The business’s 50-day moving average price is $10.44 and its 200 day moving average price is $9.37. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.73 and a beta of 1.20. Alphatec has a 12 month low of $4.88 and a 12 month high of $13.79. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. Analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Monday. StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Piper Sandler upped their price target on shares of Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. Finally, Barclays raised their target price on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.